Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lantheus HoldingsSTU:0L8 +0.23%83 Net Margin % is 19.33% as of Jun. 2026, which is 85% above its 10-year median of 10.46. GuruFocus rates STU:0L8 with a GF Score™ of 83/100 and a GF Value™ of €79.56 (Fairly Valued). The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Lantheus Holdings ranks better than 84.25% on this metric.
Lantheus Holdings (STU:0L8) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Lantheus Holdings Net Margin % Related Terms
Lantheus Holdings Net Margin % Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0L8 vs HIMS, LQDA, AMRX: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (STU:0L8) has a Net Margin % of 19.33% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Lantheus Holdings and its competitors. This is 85% above median its historical median of 10.46. According to the industry distribution chart, Lantheus Holdings ranks #151 out of 959 companies in the Drug Manufacturers industry, placing it in the top 15.7%.
Is Lantheus Holdings' Net Margin % too high?
Lantheus Holdings' current Net Margin % of 19.33% is 85% above median its 10-year median of 10.46. The Drug Manufacturers industry median Net Margin % is 5.32. Lantheus Holdings' value of 19.33% is 263.3% above this industry median. Based on the distribution chart, Lantheus Holdings ranks #151 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lantheus Holdings has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Net Margin % compare to HIMS and LQDA?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #151 out of 959 companies for Net Margin %. This places Lantheus Holdings in the top 16% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.32. Lantheus Holdings' value of 19.33% is 263.3% above this benchmark. While the company's 10-year median is 10.46 vs. the industry median of 5.32, Lantheus Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.32, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current Net Margin % of 19.33% is 263.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current Net Margin % is 19.33%, which is 85% above median its own 10-year median of 10.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (STU:0L8) is currently considered Fairly Valued. The stock's GF Value™ is €79.56, compared to a current price of €87.40 — trading 9.9% above its estimated fair value. The current Net Margin % is 19.33%, which is 85% above median its 10-year median of 10.46 and 263.3% above the Drug Manufacturers industry median of 5.32. Lantheus Holdings' overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Lantheus Holdings (STU:0L8), the current Net Margin % is 19.33% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (STU:0L8) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of €87.40 is trading 9.9% above its estimated GF Value™ of €79.56.
GuruFocus considers Lantheus Holdings to be Fairly Valued.
Key valuation signals for STU:0L8:
Net Margin %: 19.33% (85% above median its 10-year median of 10.46)
GF Value™: €79.56 vs. price of €87.40 (9.9% above fair value)
Industry Position: 263.3% above the Drug Manufacturers median (#151 of 959)
No single metric tells the full story. See the STU:0L8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
83GF Score
Get the complete analysis for STU:0L8
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0L8 has been successfully added to your 
